pharmacological tools for controlling tumour cell growth.
Pregnant Wistar-MS rats received whole body irradiation
Previous studies in our laboratory demonstrated that a signiwith 2.6 Gy γ-rays from a 60 Co source at day 20 of ficantly higher incidence of mammary tumours in the pregnancy. Control rats were fed a basal diet and were presence of the tumour promoter diethylstilbestrol (DES) is implanted with a diethylstilbestrol (DES) pellet at 30 days observed in rats irradiated during pregnancy (7, 8) . The present after weaning. In the experimental group, rats were fed a study was designed to evaluate the anti-carcinogenic activity diet containing simvastatin immediately after weaning and of simvastatin against DES-dependent promotion/progression received a DES pellet at 30 days after weaning. A high of radiation-induced mammary tumorigenesis in rats. The incidence of total mammary tumours was observed in the relationship between the chemoprevention of mammary rats fed the control diet and treated with DES for 1 year.
tumorigenesis by simvastatin and the pharmacological activities The administration of dietary simvastatin together with of this agent are discussed. DES treatment significantly decreased the incidence of mammary tumours. The development of adenocarcinoma Materials and Methods in the control rats was significantly higher than that in the rats fed the simvastatin diet. After the administration Materials of simvastatin to the experimental group for 1 year, the serum estradiol-17β concentration in these rats was [2, 4, 6, 
Introduction
Simvastatin (Figure 1 ), a synthetic derivative of lovastatin isolated from the culture filtrate of Aspergillus terreus (1) , is a prodrug of a specific inhibitor of 3-hydroxy-3-methylglutarylCoA (HMG-CoA*) reductase (2) . This compound is lactone. The dihydroxy acid form converted from simvastatin inhibits markedly HMG-CoA reductase (2) . Since HMG-CoA reductase is the rate-limiting enzyme in cholesterol biosynthesis, simvastatin has been used as an antihyperlipidemic drug. Mevalonate, produced by HMG-CoA reductase, is also the precursor of isoprenoid formation. Transfer of a farnesyl group from farnesyl pyrophosphate to p21 ras proteins is a universal post-translation modification among the cellular ras proteins. Of the 57 pregnant control rats (which were fed the basal diet, day 1) and were divided into two groups after weaning. Serving as the control administered whole body irradiation with 2.6 Gy γ-rays at day group, 57 rats were fed a basal diet and were then implanted s.c. with a DES 20 of pregnancy and then treated with DES after nursing), 50 pellet in the interscapular region at 30 days after weaning. Twenty-two rats (88%) rats developed mammary tumours during the experiwere fed a diet containing 0.03%(w/w) simvastatin beginning immediately after weaning, and received a DES pellet at 30 days after weaning. The DES mental period of 1 year (Table I ). The administration of dietary pellets were replaced every 8 weeks. The rats were examined for palpable 0.03% simvastatin together with DES implantation in the 22 mammary tumours for 1 year starting from pellet implantation. When tumours experimental rats (also irradiated in late pregnancy) signilarger than 2 cm in diameter were detected, the rats were killed by CO 2 ficantly decreased the incidence (36%) of total mammary asphyxiation and the tumours were removed. Each tumour was divided into tumours (PϽ0.0001). There were no significant differences two portions: one portion was fixed in 10% formalin for histopathological examination and the other was trimmed off surrounding normal tissue and between the two groups in the number of mammary tumours immediately frozen for receptor assays. Iball's index was calculated as follows:
per tumour-bearing rat or in the average latency period until the ratio of incidence (%) to the average latency period in days was multiplied appearance of the first mammary tumour. The Iballs index for by 100 (9) .
overall tumour development in the simvastatin-fed rats was The final body and organ weights are summarized in Table II. and triglyceride were assayed by commercially available kits.
No change of body weight was observed after administration

Immunohistochemical detection of prolactin in pituitary glands
of simvastatin for 1 year. The simvastatin feeding of DES-diet was markedly reduced, to 20% of that observed in rats fed the control diet (PϽ0.05). No significant differences in glands by simvastatin. In the irradiated rats fed the control diet, the mammary glands showed small alveolar buds due to the DES implantation ( Figure 4 ). Alveolar buds with lactiferous ducts were also observed throughout the mammary glands of the irradiated rats treated with DES together with simvastatin effect on the mammary glands developed by DES implantation. ER and PgR in mammary tumours incidence (39%, PϽ0.05) of ER ϩ PgR ϩ tumours. Table IV shows the receptor concentrations and Kd values obtained Many (75%) of the mammary tumours which developed in the rats fed the control diet were of the ER ϩ PgR ϩ type, and when the ER and PgR in the cytosol fraction were analysed with a Scatchard plot. The maximum binding sites for ER and only one tumour (2.5%) was ER -PgR - (Table III) . Simvastatinfed rats showed significantly increased incidence (31%, PgR in the fibroadenomas developed in the simvastatin-fed rats were significantly lower than those in the control. Also, PϽ0.05) of ER -PgR -tumours and significantly decreased translational farnesylation (21) . HMG-CoA reductase catalyses available for the farnesylation of p21 ras . Ura et al. (23) have reported the cytotoxic effect of simvastatin on human pancreatic adenocarcinoma cells that have the mutant Ki-ras oncogene at codon 12. The proliferation of human mammary (26) and an enhancement of enzyme stability (27) in rats.
b Maximum binding sites (fmol/mg protein).
Therefore, it is unlikely that one of the mechanisms in the c ϫ 10 Ϫ9 M.
chemoprevention of mammary tumours by long-term treatment with simvastatin is to suppress the farnesylation of p21 ras the maximum binding sites for both receptors in the adenocarciproteins. nomas obtained from the simvastatin-fed rats were reduced, Addeo et al. (5) have reported that the growth of ERbut there was no significant difference between the control mammary tumour cells was inhibited by simvastatin. In our and experimental groups. The Kd values for ER in the present study, the maximum binding sites for ER and PgR in adenocarcinomas were significantly decreased by simvastatin both adenocarcinoma and fibroadenoma were reduced by feeding, and slightly, but not significantly, reduced in the simvastatin feeding, therefore, it would be considered to fibroadenomas. Conversely, the Kd value for PgR was signihave preventive activity on the growth of hormone-dependent ficantly increased (PϽ0.05) in the fibroadenomas, whereas, no tumour cells, and the number of ER -PgR -tumours was also change was observed in the adenocarcinomas.
increased in the simvastatin-treated rats. The results of the receptor analysis revealed that simvastatin somehow modulated Discussion the hormone-dependency of the radiation-induced mammary tumours. The mechanism for the negative regulation on those The results of the present study clearly demonstrated that dietary simvastatin inhibited the DES-dependent promotion/ receptors expression by simvastatin is still unclear. The inhibition of tumour cell growth by HMG-CoA reductase inhibitor progression phase of radiation-induced mammary tumorigenesis. Although a low level (20% of the control value) of did not show specificity for the cell transformation which is dependent upon farnesylated ras protein (28) . Simvastatin was serum estradiol-17β was observed in the rats fed the simvastatin diet, the serum concentration of prolactin was not reduced.
able to induce G 1 arrest of the cell cycle of ER ϩ mammary tumour cells in the absence of oestrogen (29) . Since, in Prolactin concentrations in both the control rats and simvastatin-fed rats were maintained during the experimental period at the present study, simvastatin markedly reduced the serum concentration of estradiol-17β, an inhibition of the proliferation a high level, which was the same level as that in the lactating period, because of the continuous administration of DES.
of ER ϩ tumour cells may have occurred in the present experiment. Simvastatin did not reduce the high concentration of prolactin secreted from the DES-stimulated pituitary glands, but
In conclusion, the DES-dependent promotion/progression of radiation-induced mammary tumorigenesis was inhibited by showed chemoprevention against the DES-dependent promotion/progression of radiation-induced mammary tumorisimvastatin. The administration of dietary simvastatin retarded the development of mammary tumours of ER ϩ PgR ϩ type or genesis. In our previous studies of chemoprevention of radiation-induced mammary tumours, a decrease in the prolacthe receptor concentrations were lower than those of tumours obtained in the rats fed the control diet. tin level under an increased concentration of estradiol-17β was seen by administration of dietary dehydroepiandrosterone (16) or 2-{p-[2-(p-chlorobenzamide)-ethyl]phenoxy}-2-methylpro
